Purpose: Lung cancer is the most common cause of death from cancer worldwide, largely due to late diagnosis. Thus, there is an urgent need to develop new approaches to improve the detection of early-stage lung cancer, which would greatly improve patient survival. Experimental design: The quantitative protein expression profiles of microvesicles isolated from the sera from 46 lung cancer patients and 41 high-risk non-cancer subjects were obtained using a mass spectrometry method based on a peptide library matching approach. Results: We identified 33 differentially expressed proteins that allow discriminating the two groups. We also built a machine learning model based on serum protein expression profiles that can correctly classify the majority of lung cancer cases and that highlighted a decrease in the levels of Arysulfatase A (ARSA) as the most discriminating factor found in tumors. Conclusions and clinical relevance: Our study identified a preliminary, non-invasive protein signature able to discriminate with high specificity and selectivity early-stage lung cancer patients from high-risk healthy subjects. These results provide the basis for future validation studies for the development of a non-invasive diagnostic tool for lung cancer.

Serum proteomics profiling identifies a preliminary signature for the diagnosis of early-stage lung cancer / R. Gasparri, R. Noberini, A. Cuomo, A. Yadav, D. Tricarico, C. Salvetto, P. Maisonneuve, V. Caminiti, G. Sedda, A. Sabalic, T. Bonaldi, L. Spaggiari. - In: PROTEOMICS. CLINICAL APPLICATIONS. - ISSN 1862-8346. - (2023 Jan 16), pp. e2200093.1-e2200093.10. [Epub ahead of print] [10.1002/prca.202200093]

Serum proteomics profiling identifies a preliminary signature for the diagnosis of early-stage lung cancer

T. Bonaldi
Penultimo
Supervision
;
L. Spaggiari
Ultimo
2023

Abstract

Purpose: Lung cancer is the most common cause of death from cancer worldwide, largely due to late diagnosis. Thus, there is an urgent need to develop new approaches to improve the detection of early-stage lung cancer, which would greatly improve patient survival. Experimental design: The quantitative protein expression profiles of microvesicles isolated from the sera from 46 lung cancer patients and 41 high-risk non-cancer subjects were obtained using a mass spectrometry method based on a peptide library matching approach. Results: We identified 33 differentially expressed proteins that allow discriminating the two groups. We also built a machine learning model based on serum protein expression profiles that can correctly classify the majority of lung cancer cases and that highlighted a decrease in the levels of Arysulfatase A (ARSA) as the most discriminating factor found in tumors. Conclusions and clinical relevance: Our study identified a preliminary, non-invasive protein signature able to discriminate with high specificity and selectivity early-stage lung cancer patients from high-risk healthy subjects. These results provide the basis for future validation studies for the development of a non-invasive diagnostic tool for lung cancer.
biomarker; early diagnosis; lung cancer; machine learning; mass spectrometry; serum
Settore BIO/13 - Biologia Applicata
Settore MED/06 - Oncologia Medica
Settore BIO/10 - Biochimica
16-gen-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
Proteomics Clinical Apps2023 Gasparri.pdf

accesso aperto

Descrizione: Research Article
Tipologia: Publisher's version/PDF
Dimensione 1.2 MB
Formato Adobe PDF
1.2 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/952669
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact